BioXcel Therapeutics, Inc. — Form 8-K
Filed August 3, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 78/100
What the filing says
BioXcel (market value ~$11M) amended its credit agreement with Oaktree Capital Management and Q Boost Holding LLC (Qatar Investment Authority) on July 31, 2026. Key changes: (1) deferred $9.02M payment from June 30 to August 31, 2026; (2) reduced minimum liquidity requirement from $7.5M to $6.25M post-amendment; (3) required company to enter definitive agreements by August 10, 2026 for either full debt repayment or alternative capital transaction acceptable to lenders; (4) froze executive compensation and benefits modifications through August 31, 2026. This is the eleventh amendment since April 2022.
Why this rating
Repeated amendments (11 since 2022), tightened covenants, mandatory transaction deadline, and tight liquidity constraints signal severe distress. Debt payment deferral and compensation freeze indicate lender control. Material relative to $11M market cap.
See more from August 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.